Bortezomib will increase the level or influence of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Improved flibanserin adverse results may perhaps take place if coadministered with multiple weak CYP3A4 inhibitors. Other effects, such as a pores and skin rash, might not be critical but may well cause concern. https://johnw230kek6.sasugawiki.com/user